Investigational drug · Phase 2
R2R01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Kidney Injury, Hepatorenal Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "R2R01"
First trial start
2023
Jun 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "R2R01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Kidney Injury
- Hepatorenal Syndrome
Approved drugs for the same conditions: Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "R2R01" as an intervention, largest first.
- Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney InjuryPivotal-lookingRecruiting
River 2 Renal Corp.Industry
NCT07625553 · 430 participants (planned) · Start Apr 7, 2026 · Primary completion Apr 1, 2027
Drug: R2R01 · For: Acute Kidney Injury
Sites: Milan, Italy
River 2 Renal Corp.Industry
NCT05875948 · 95 participants (planned) · Start Jun 30, 2023 · Primary completion Dec 2024
Drug: R2R01; Terlipressin · For: Hepatorenal Syndrome; Acute Kidney Injury
Sites: San Francisco, California; Atlanta, Georgia; Boston, Massachusetts · 7 sites in all
River 2 Renal Corp.Industry
NCT06264310 · 33 participants · Start Mar 1, 2024 · Primary completion Nov 4, 2024
Drug: Placebo; R2R01 · For: Heart Failure; Worsening Heart Failure (WHF)
Sites: Fairhope, Alabama; Fort Meyers, Florida; Hialeah, Florida · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Optimization of Single Relaxin B-Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases.
Mallart S, Ingenito R, Magotti P, et al. · J Med Chem 2025
- R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases.
Poirier B, Pasquier O, Chenede X, et al. · Br J Pharmacol 2024
Also in development for Acute Kidney Injury
- QRX-3EseronatePhase 32 trials
Ebima Clifford Okundaye · Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- AZD4144Phase 21 trial
AstraZeneca · Sepsis, Acute Kidney Injury
- LSALT PeptideMetablokPhase 21 trial
Arch Biopartners Inc. · Acute Kidney Injury, Cardiac Surgery
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.